A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors.

Trial Profile

A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Carboplatin; Talabostat; Temozolomide
  • Indications Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Hepatic tumours; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Apr 2010 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov record.
    • 06 Apr 2010 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov record.
    • 06 Apr 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top